FY2025 EPS Estimates for Kura Oncology Boosted by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Kura Oncology in a research note issued on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($2.21) per share for the year, up from their previous forecast of ($2.94). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

A number of other research firms have also weighed in on KURA. Jefferies Financial Group cut their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Bank of America cut their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. StockNews.com downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Stock Up 8.0 %

Shares of KURA opened at $7.85 on Friday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $633.93 million, a P/E ratio of -3.33 and a beta of 0.85. The company’s 50-day moving average price is $7.81 and its 200 day moving average price is $12.58. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently bought and sold shares of KURA. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock valued at $579,000 after buying an additional 7,722 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Kura Oncology during the third quarter valued at approximately $298,000. Charles Schwab Investment Management Inc. boosted its stake in Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares in the last quarter. Algert Global LLC boosted its stake in Kura Oncology by 4.4% in the third quarter. Algert Global LLC now owns 272,276 shares of the company’s stock worth $5,320,000 after purchasing an additional 11,493 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Kura Oncology in the third quarter worth $596,000.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,729 shares of company stock valued at $92,307. Company insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.